<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544634</url>
  </required_header>
  <id_info>
    <org_study_id>2011RC16</org_study_id>
    <secondary_id>2011-002512-89</secondary_id>
    <nct_id>NCT01544634</nct_id>
  </id_info>
  <brief_title>Beta Blocker Therapy in Mild to Moderate Asthmatics</brief_title>
  <acronym>ANDA1</acronym>
  <official_title>Evaluation of Any Steroid Sparing Effect of Beta Blocker Therapy on Airway Hyper-responsiveness in Stable, Mild to Moderate Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current asthma medicines include inhalers. A common type of inhaler is called a
      'beta-agonist' (e.g. salbutamol). They improve asthma symptoms by stimulating areas in the
      airway causing it to widen. Although these drugs are useful short term, long term use can
      make asthma worse in some people.

      'Beta-blockers' are the complete opposite type of medication. Just now they are avoided in
      patients with asthma. Beta-blockers cause problems in asthmatics in the short term, including
      severe asthma attacks.

      The other mainstay of inhaler treatment for asthma is inhaled steroid or 'preventer'
      medication. These work by dampening down the inflammation in the lungs that occurs in asthma.

      New research has suggested that longer term use of beta-blockers can also reduce airway
      inflammation which may improve asthma control. This research was done in asthmatic patients
      who didn't need inhaled steroids to control their asthma. At the moment the investigators are
      studying to see if there is a benefit of beta-blocker use for asthma over and above
      asthmatics own usual doses of inhaled steroids.

      In this study, the investigators will be trying to find out if adding a beta blocker to a
      smaller dose of steroid inhaler has the same effect on asthma control as just using a higher
      dose of steroid inhaler by itself.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2012</start_date>
  <completion_date type="Actual">May 25, 2013</completion_date>
  <primary_completion_date type="Actual">May 25, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Histamine provocative concentration causing 20% fall in FEV1 (PC20)at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Measurement of airway hyper-reactivity (a hallmark of asthma).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Impulse oscillometry parameters at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Change in: Resistance at 5Hz, Resistance at 20Hz, Reactance at 5Hz, Frequency of resonance, Area under reactance curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry parameters at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Change in: Forced expiratory volume in 1 second (FEV1); forced vital capacity (FVC); forced expriatory flow between 25-75% of vital capacity; FEV1/FVC ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting heart rate at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Abosolute change in heart rate at 6 weeks will be a secondary outcome. Participants will measure their own heart rate at home on a daily basis and compare this to a given cut-off value, below which they will be advised to contact a trial doctor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting blood pressure at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Blood pressure will be monitored at each visit, or if patients develop symptoms that may be due to low blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exhaled tidal nitric oxide levels at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overnight urinary cortisol/creatinine ratio (OUCC) at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
    <description>Systemic effects from inhaled corticosteroids can be measured using OUCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom scores (Asthma control questionnaire and Asthma quality of life questionnaire) at 6 weeks</measure>
    <time_frame>Change from baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Propranolol + Low dose Qvar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + high dose Qvar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.</description>
    <arm_group_label>Propranolol + Low dose Qvar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks</description>
    <arm_group_label>Placebo + high dose Qvar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qvar 50</intervention_name>
    <description>Qvar 50, 1 puff bd for 6 weeks</description>
    <arm_group_label>Propranolol + Low dose Qvar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qvar 100</intervention_name>
    <description>Qvar 100, 2 puffs bd for 6 weeks</description>
    <arm_group_label>Placebo + high dose Qvar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable mild to moderate asthma

          -  Histamine PC20 &lt;/= 8mg/ml

          -  Receiving inhaled corticosteroid 0-1000ug daily (BDP equivalent dose)

          -  FEV1 &gt; 60% predicted

          -  Diurnal variability &lt; 30%

          -  Reliever use &lt;/= 8puffs/day

          -  ECG demonstrating sinus rhythm

        Exclusion Criteria:

          -  Uncontrolled symptoms of asthma

          -  Systolic BP&lt;110mmHg

          -  Heart rate&lt;60bpm

          -  Pregnancy or lactation

          -  Heart block

          -  Heart rate limiting medications currently prescribed

          -  Asthma exacerbation within 6 months of study commencement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Anderson, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian J Lipworth, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma and Allergy Research Group, University of Dundee</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Morales DR, Guthrie B, Lipworth BJ, Donnan PT, Jackson C. Prescribing of Î²-adrenoceptor antagonists in asthma: an observational study. Thorax. 2011 Jun;66(6):502-7. doi: 10.1136/thoraxjnl-2011-200067. Epub 2011 Apr 1.</citation>
    <PMID>21459857</PMID>
  </reference>
  <reference>
    <citation>Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, Parra S, Bond RA. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115-24. Epub 2007 Jul 4.</citation>
    <PMID>17689122</PMID>
  </reference>
  <reference>
    <citation>Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008 Mar;38(3):256-62. Epub 2007 Dec 20.</citation>
    <PMID>18096872</PMID>
  </reference>
  <reference>
    <citation>Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O'Connor BJ, Page C, Bond RA. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134-41. Epub 2007 Jul 17.</citation>
    <PMID>17703976</PMID>
  </reference>
  <reference>
    <citation>Lipworth BJ, Williamson PA. Think the impossible: beta-blockers for treating asthma. Clin Sci (Lond). 2009 Oct 12;118(2):115-20. doi: 10.1042/CS20090398.</citation>
    <PMID>19807697</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>William J Anderson</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Steroid sparing agent</keyword>
  <keyword>Airway hyper-responsiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

